Currently, targeted therapy has been successfully used in treating patients with other tumors with BRAF V600E mutation, namely, melanoma, non small cell lung cancer (NSCLC), papillary thyroid cancer, hairy cell leukemia, colon cancer in combination with Cetuximab. Here, BRAF is linked to non-small cell lung carcinoma.